Skip to main content
David Reardon, MD, Oncology, Boston, MA

DavidAllenReardonMD

Oncology Boston, MA

Hematologic Oncology, Neuro-Oncology

Clinical Director, Center for Neuro-Oncology Dana-Farber Cancer Institute Boston, MA

Dr. Reardon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Reardon's full profile

Already have an account?

  • Office

    450 Brookline Avenue, G460f
    Center For Neuro-Oncology, Dana-Farber Cancer Institute
    Boston, MA 02215
    Phone+1 617-632-6172
    Fax+1 617-632-4773

Education & Training

  • University of Michigan
    University of MichiganFellowship, Pediatric Hematology/Oncology, 1990 - 1993
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Pediatrics, 1987 - 1989
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 1986

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • CT State Medical License
    CT State Medical License 2022 - 2025
  • MA State Medical License
    MA State Medical License 2011 - 2025
  • NC State Medical License
    NC State Medical License 2000 - 2011
  • ME State Medical License
    ME State Medical License Active through 2000
  • TN State Medical License
    TN State Medical License 1995 - 2000
  • MI State Medical License
    MI State Medical License 1989 - 1998

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Socioeconomic Disparities Associated with MGMT Promoter Methylation Testing for Patients with Glioblastoma  
    David Reardon, MD, JAMA Oncology
  • Socioeconomic Disparities Associated with MGMT Promoter Methylation Testing for Patients with Glioblastoma  
    David Reardon, MD, JAMA Oncology
  • Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma  
    David A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology

Lectures

  • Concepts for Immunotherapies in Gliomas 
    2019 ASCO Annual Meeting - 6/1/2019

Authored Content

  • Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
  • Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
  • Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020

Press Mentions

  • In Mouse Study, New Gel Therapy Stops Dangerous Brain Tumors
    In Mouse Study, New Gel Therapy Stops Dangerous Brain TumorsApril 26th, 2023
  • Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neuro-Oncology Medical Advisory Board
    Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neuro-Oncology Medical Advisory BoardMarch 21st, 2022
  • A Revolutionary Clinical Trial Is Testing Customized Vaccines That Target Cancerous Tumors
    A Revolutionary Clinical Trial Is Testing Customized Vaccines That Target Cancerous TumorsNovember 4th, 2021
  • Join now to see all

Grant Support

  • Translational Clinical Trials For Primary CNS TumorsNational Institute Of Neurological Disorders And Stroke2009–2012
  • Core--Phase I/II Clinical TrialsNational Cancer Institute2007–2008
  • Translational Clinical Trials In Neuro-OncologyNational Institute Of Neurological Disorders And Stroke2004–2008
  • Core-3-Phase I/II Clinical TrialsNational Cancer Institute2004–2006
  • Phase II Study Of 44gy From 131i-81c6 For CNS TumorsNational Cancer Institute2003–2004
  • Core--Phase I / II Clinical Trials CoreNational Cancer Institute2002

Professional Memberships